Skip to main content
European Commission logo print header

Advancement of hearing assessement methods and devices - immediate intervention

Objetivo

Within the past 3-4 years, scientists and clinicians have demonstrated the feasibility, reliability, and effectiveness of early detection of infants with hearing loss through universal newborn hearing screening (UNHS) based onotoacoustic emissions (Oases). OAE technology has been entirely developed in the Equals as a result of previous EC projects (Biomedicine & Health). UNHS is becoming standard of care in the most advanced maternity clinics. Oases are produced byte outer hair cells. They contain contractile proteins, play a crucial role in peripheral coding under the control of higher neural centres and are essential to normal cochlear function. Absence or alterations of Oases is the method to assess even mild peripheral hearing losses. These technologies were entirely developed in Europe and are being applied by European manufacturers who still maintain the technical leadership in the field (with a share of almost 90% of the whole market).

Convocatoria de propuestas

Data not available

Régimen de financiación

THN - Thematic network contracts

Coordinador

NATIONAL RESEARCH COUNCIL OF ITALY
Aportación de la UE
Sin datos
Dirección
Piazza Leonardo Da Vinci 32
20133 MILANO
Italia

Ver en el mapa

Coste total
Sin datos

Participantes (50)